By continuing, you agree to the Terms of Service.
This website uses cookies to enhance your browsing experience. Learn More.
Essential Cookies
Optional Cookies
Login
Logo for company Reckitt Benckiser Group plc

Reckitt Benckiser Group plc (RBGLY)

OTC Market Data in USD, Fundamentals in GBP
$15.71
+$0.06
+0.38%
Last Update: 11 Sept 2025, 19:59
$54.03B
Market Cap
0.00
P/E Ratio (TTM)
5.77%
Forward Dividend Yield
$11.73 - $15.82
52 Week Range

RBGLY Stock Price Chart

Explore Reckitt Benckiser Group plc interactive price chart. Choose custom timeframes to analyze RBGLY price movements and trends.

RBGLY Company Profile

Discover essential business fundamentals and corporate details for Reckitt Benckiser Group plc (RBGLY) to support your stock research and investment decisions.

Sector

Consumer Defensive

Industry

Household & Personal Products

IPO Date

15 Oct 2008

Employees

37.90K

CEO

Kristoffer Loe Licht

Description

Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products in the United Kingdom, the United States, China, India, and internationally. The company offers acne treatment creams, facial washes, and cleansing pads; disinfection, hygiene, and first aid products; condoms, sex toys, and lubricants; heartburn and indigestion solutions; and cough and chest congestion, multi-symptom, and sinus remedies for adults and children under the Clearasil, Dettol, Durex, Gaviscon, and Mucinex brands. It also provides analgesics; sore throat medications; and hair removal products under the Nurofen, Strepsils, and Veet brands. In addition, the company offers fragrances and devices; water softeners; home cleaning products; dish washes; toilet cleaners; disinfectants; sprays, baits, and plug-ins for pest control; stain removals; fabric washing; and other hygiene products under the Air Wick, Calgon, Cillit Bang, Finish, Harpic, Lysol, Mortein, Vanish, and Woolite brands, as well as analgesics, adult nutrition products, iron-fortified hypoallergenic baby formula, products for joint issues, and infant and toddler nutrition products, as well as vitamins, minerals, and supplements under the Biofreeze, Airborne, Mead Johnson, Move Free, Enfamil, and Nutramigen brands. Further, it provides probiotics, sore throat pain relief products, Omega products, brain health support products, cleaning and carpet cleaning products, septic tank system treatment products, cough syrups, plant-based laundry products, probiotics, and lubricants under the Digestive Advantage, Cepacol, MegaRed, Neuriva, Easy-Off, RID-X, Delsym, Botanical Origin, Bodi-Ome, and K-Y brands. The company was founded in 1819 and is headquartered in Slough, the United Kingdom.

RBGLY Financial Timeline

Browse a chronological timeline of Reckitt Benckiser Group plc corporate events including earnings releases, dividend announcements, and stock splits.

Upcoming earnings on 4 Mar 2026

Dividend declared on 25 Jul 2025

A dividend of $0.23 per share was announced, adjusted to $0.23. The dividend will be paid on 25 Sept 2025.

Earnings released on 24 Jul 2025

EPS came in at $0.38 falling short of the estimated $0.44 by -13.90%, while revenue for the quarter reached $9.45B , beating expectations by +167.84%.

Earnings released on 23 Apr 2025

EPS came in at $0.51 surpassing the estimated $0.39 by +29.15%, while revenue for the quarter reached $8.76B , missing expectations by -3.78%.

Dividend declared on 14 Mar 2025

A dividend of $0.31 per share was announced, adjusted to $0.31. The dividend was paid on 5 Jun 2025.

Earnings released on 24 Jul 2024

EPS came in at $2.04 surpassing the estimated $0.39 by +416.98%, while revenue for the quarter reached $9.07B , missing expectations by -0.37%.

Dividend declared on 24 Jul 2024

A dividend of $0.21 per share was announced, adjusted to $0.21. The dividend was paid on 23 Sept 2024.

Earnings released on 28 Feb 2024

EPS came in at $0.71 surpassing the estimated $0.37 by +92.02%, while revenue for the quarter reached $9.05B , beating expectations by +0.61%.

Dividend declared on 28 Feb 2024

A dividend of $0.29 per share was announced, adjusted to $0.29. The dividend was paid on 3 Jun 2024.

Earnings released on 26 Jul 2023

EPS came in at $2.17 surpassing the estimated $0.43 by +402.90%, while revenue for the quarter reached $9.43B , beating expectations by +1.62%.

Dividend declared on 26 Jul 2023

A dividend of $0.20 per share was announced, adjusted to $0.20. The dividend was paid on 22 Sept 2023.

Earnings released on 1 Mar 2023

EPS came in at $1.69 surpassing the estimated $0.41 by +311.89%, while revenue for the quarter reached $9.30B , missing expectations by -0.53%.

Dividend declared on 1 Mar 2023

A dividend of $0.27 per share was announced, adjusted to $0.27. The dividend was paid on 1 Jun 2023.

Earnings released on 26 Oct 2022

EPS came in at $2.28 surpassing the estimated $0.36 by +534.21%, while revenue for the quarter reached $8.36B , beating expectations by +2.94%.

Dividend declared on 27 Jul 2022

A dividend of $0.18 per share was announced, adjusted to $0.18. The dividend was paid on 21 Sept 2022.

Earnings released on 29 Apr 2022

EPS came in at $3.20 surpassing the estimated $0.40 by +698.60%, while revenue for the quarter reached $8.95B , missing expectations by -0.17%.

Dividend declared on 11 Mar 2022

A dividend of $0.27 per share was announced, adjusted to $0.27. The dividend was paid on 16 Jun 2022.

Earnings released on 26 Oct 2021

EPS came in at -$3.34 falling short of the estimated $0.39 by -947.63%, while revenue for the quarter reached $9.12B , missing expectations by -2.24%.

Dividend declared on 27 Jul 2021

A dividend of $0.19 per share was announced, adjusted to $0.20. The dividend was paid on 22 Sept 2021.

Earnings released on 28 Apr 2021

EPS came in at $0.21 falling short of the estimated $0.44 by -52.04%, while revenue for the quarter reached $9.63B , missing expectations by -1.49%.

Dividend declared on 14 Apr 2021

A dividend of $0.29 per share was announced, adjusted to $0.28. The dividend was paid on 21 Jun 2021.

Earnings released on 20 Oct 2020

EPS came in at $1.88 surpassing the estimated $0.43 by +333.08%, while revenue for the quarter reached $8.61B , beating expectations by +0.41%.

RBGLY Stock Performance

Access detailed RBGLY performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.

Explore Related Stocks

Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.

Discover More
Command Palette
Search for a command to run